Q&A with Pedro Teixeira of Kinetikos Health

Spotlight on MedTech in South Yorkshire

By Philippa Hedley-Takhar

On Monday 20 June, Kinetikos Health, one of the companies currently on our P4SY Accelerator Programme, will present their research into improving management of Parkinson’s at the Neurology Academy, Sheffield. Full details of the event are available here.

Ahead of the event, we sat down with Pedro Teixeira from Kinetikos Health to understand what the company hopes to accomplish. 

Q. Tell us about the company and its goals. 

A. Kinetikos Health is a digital health company on a mission to revolutionise the standard of care for people with Parkinson’s. We exist to help healthcare providers, businesses and patients make patient monitoring more efficient and meaningful, towards improving the individual’s quality of life. We do this by combining research with technology to tackle the number one cause of years lived with a disability. The company was established in 2015 and has its headquarters in Portugal, with operations in Sheffield, UK.


About the Author
Philippa Hedley-Takhar

Philippa Hedley-Takhar

P4 SY Programme Manager

Q. How does your platform help patients and clinicians?

A. Our technology combines a medical-grade platform for healthcare providers and a Parkinson’s phone app for patients. The latter provide continuous monitoring of movement, symptomatology, and medication adherence in the patients waking hours. This helps clinicians to better manage their patients, individuals their own condition, and institutions their resources, leading to increased healthcare efficiency and improvements to the patient’s quality of life. 

The benefits are significant, from early detection of deterioration in a patient’s condition to the ability to track whether patients are taking their medication. It gives individuals more control and visibility into the management of their condition and lets clinicians prioritise patients for follow-up, which is an important part of how we can help healthcare providers allocate resources more efficiently. We believe that by enabling better shared decision making between clinicians and the individuals they treat, we can improve outcomes. 

Q. What are the big challenges to getting this tech adopted?

A. The biggest challenge to getting this technology adopted is engaging with clinicians and multi-disciplinary teams, often due to their workload pressure, and engage with people living with Parkinson’s and their families. However, it’s really critical that we develop these relationships, as well as with the wider Parkinson’s community and charities, as all these stakeholders are an important part of the adoption process – particularly to understand context and pathways of care. We believe our technology will help clinicians reduce unnecessary outpatient visits and avoidable hospitalisations, through improved communication with people living with Parkinson’s.

Q. Final question, where do you see the company in five years?

A. We are on a journey to evolve from a digital management tool for a pure movement disorder like Parkinson’s to address other conditions where mobility is relevant, like lower-back pain, depression, and obesity. The goal in five years is to start serving the US market. By addressing conditions like the ones we mention above, this represents a $600 million TAM and corresponds to a burden in excess of $850 billion burden which we can minimise.

Thanks to Pedro for chatting with us. If you would like to attend this presentation in partnership with the Neurology Academy in Sheffield, you can register to attend here.

P4 SY is a MedTech-focused accelerator based in South Yorkshire and a part of TEAM SY.

TEAM SY is an ERDF part-funded project delivered by Capital Enterprise and Barnsley Council.